Oh I missed the most important one. Roche's anti-TIGIT in NSCLC is not performing what they have hoped for. The position for combining with their Tecentriq remains vacant. For Roche, eyeing on the huge market of lung cancer being chewed up by Merck and BMS mostly, I bet that hurt!
Oh I missed the most important one. Roche's anti-TIGIT in NSCLC...
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.8¢ |
Change
0.033(11.0%) |
Mkt cap ! $468.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 35.0¢ | 31.5¢ | $1.118M | 3.397M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 98189 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 90099 | 6 |
View Market Depth
| Last trade - 11.16am 01/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |